Merck & Co Inc. (MRK) News Headlines

▮ More

Date

Headline

5/21/2019 7:18:00 AM Merck To Acquire Peloton - Quick Facts

5/21/2019 7:02:19 AM Merck To Acquire Privately Held Peloton Therapeutics

5/20/2019 7:37:26 PM Merck's Keytruda Fails Late Stage Clinical Trial

5/7/2019 7:18:20 AM Merck: Phase 3 Trial Of BELSOMRA C-IV Meets Primary Efficacy Endpoints

5/7/2019 6:54:26 AM Merck Says BELSOMRA C-IV Meets Primary Efficacy Endpoint In Phase 3 Trial

4/30/2019 6:53:15 AM Merck & Co Inc. Q1 adjusted earnings Beat Estimates

4/30/2019 6:49:03 AM Merck Q1 GAAP EPS $1.12; Non-GAAP EPS $1.22

4/29/2019 2:19:02 AM AstraZeneca: Lynparza Receives Positive CHMP Opinion For Expanded Indication

4/22/2019 8:25:33 AM Merck: FDA Approves KEYTRUDA-Inlyta Combination - Quick Facts

4/22/2019 6:49:51 AM Merck Says FDA Approved KEYTRUDA In Combination With Inlyta

4/10/2019 2:16:29 AM AstraZeneca: EU Spproves Lynparza As Monotherapy For Germline BRCA1/2-mutations

4/5/2019 7:42:01 AM Endo Unit Begins Shipping Generic Version Of Merck's PROVENTIL - Quick Facts

4/4/2019 7:09:37 AM Myriad, AstraZeneca And Merck Expand Companion Diagnostic Partnership

4/2/2019 7:05:00 AM Merck Reports Successful Completion Of Cash Tender Offer For Immune Design

4/2/2019 6:52:48 AM Merck Completes Tender Offer To Buy Immune Design

4/1/2019 8:58:21 AM Merck Announces Post-hoc Analysis From KEYNOTE-189 Trial - Quick Facts

4/1/2019 8:41:39 AM Merck Reports First-time Presentation Of Results From Phase 3 KEYNOTE-189 Trial

4/1/2019 2:37:10 AM AstraZeneca: Selumetinib Gets US Breakthrough Therapy Designation

4/1/2019 2:06:09 AM AstraZeneca Says Selumetinib Gets Breakthrough Therapy Designation

3/26/2019 7:16:18 AM Biotech Stocks Facing FDA Decision In April